Medical therapy of neurocardiogenic syncope
- PMID: 11407106
- DOI: 10.1016/s0733-8651(05)70208-3
Medical therapy of neurocardiogenic syncope
Abstract
Neurocardiogenic syncope, alternatively called vasovagal, vasodepressor, or neurally mediated syncope, is a clinical syndrome faced by many clinicians. Its pathophysiology is complicated and not fully understood. Multiple pharmacologic therapies have been evaluated, with no clear ideal agent. Decisions regarding tilt-table testing, selection of pharmacotherapy, and assessment of drug efficacy are not straightforward. This article attempts to assess these issues.
Similar articles
-
Pathophysiology and management of neurocardiogenic syncope.Am J Manag Care. 2003 Apr;9(4):327-34; quiz 335-6. Am J Manag Care. 2003. PMID: 12703677
-
Strategy for the management of vasovagal syncope.Drugs Aging. 2002;19(3):179-202. doi: 10.2165/00002512-200219030-00003. Drugs Aging. 2002. PMID: 12027777 Review.
-
Syncope: pathophysiology, diagnosis, and pharmacotherapy.Ann Pharmacother. 1996 Sep;30(9):994-1005. doi: 10.1177/106002809603000915. Ann Pharmacother. 1996. PMID: 8876862 Review.
-
Management of vasovagal syncope.J Cardiovasc Electrophysiol. 1999 Jun;10(6):874-86. doi: 10.1111/j.1540-8167.1999.tb00270.x. J Cardiovasc Electrophysiol. 1999. PMID: 10376927
-
Neurocardiogenic syncope: latest pharmacological therapies.Expert Opin Pharmacother. 2006 Jun;7(9):1151-62. doi: 10.1517/14656566.7.9.1151. Expert Opin Pharmacother. 2006. PMID: 16732702 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources